MSD has received the EC approval for Enflonsia, indicated to prevent RSV lower respiratory tract disease in newborns and infants during their initial RSV season.

Trump's executive order sets out to speed up the review of psychedelics, while supporting research into this burgeoning field.

UCB has signed a definitive agreement to acquire Neurona Therapeutics in a deal worth up to $1.15bn, adding the latter’s lead asset NRTX-1001 to its epilepsy portfolio.

Kailera's IPO will allow the biotech to take oral and injectable forms of its lead candidate, ribupatide, through late-stage obesity trials.

Daiichi Sankyo has partnered with Interna Therapeutics to develop targeted delivery solutions based on molecular nano motor (MNM) technology.

Boehringer Ingelheim and Zai Lab have entered into a clinical collaboration to investigate a dual DLL3-targeting approach for patients with ES-SCLC and other NECs.

As in vivo cell therapies enter clinical trials, suppliers tackle the technical and logistical barriers to commercial viability.

The FDA requires Eli Lilly to evaluate “unexpected serious” risks associated with Foundayo – some of which have been addressed by the ACHIEVE-4 trial.

Adcendo, a clinical-stage biotechnology company developing ADCs for cancer treatment, has raised $75m in a Series C funding round.

Aligos Therapeutics and Xiamen Amoytop Biotech are to develop and commercialise pevifoscorvir sodium in Greater China for chronic HBV infection.

Eli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash.

Amazon has already collaborated with Memorial Sloan Kettering Cancer Center with its AI drug discovery software.